Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.39 |
| ▸ | CTSK | P43235 | 10/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923086 | 0.78 | RAB9A (0.36) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL279792 | 0.75 | AAK1 (0.38) | CTSSCTSKCTSBTRPA1EGLN2 | |
| SCHEMBL1966568 | 0.75 | NR1H2 (0.39) | CTSLMEN1NPC1GAARAB9A | |
| SCHEMBL1854385 | 0.75 | KDM4E (0.37) | CTSLMEN1NPC1GAARAB9A | |
| SCHEMBL16678680 | 0.74 | HSP90AA1 (0.43) | CTSKMEN1KMT2A | |
| SCHEMBL15043244 | 0.73 | CTSS (0.37) | CTSSCTSKCTSLCTSBTRPA1 | |
| SCHEMBL9920358 | 0.70 | TSHR (0.38) | MEN1NPC1RAB9AKMT2ACA12 | |
| SCHEMBL1036742 | 0.69 | CTSS (0.47) | CTSSCTSKCTSLCTSB | |
| SCHEMBL8836159 | 0.69 | NOTUM (0.42) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL9980547 | 0.67 | APLNR (0.36) | MEN1NPC1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023147372-A1 | INHIBITORS OF CDK4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3988551-A1 | CDK KINASE INHIBITOR | Beijing Benicall Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220098201-A1 | THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-31 | — | — | US | disclosed |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| CN-110092787-B | Preparation and application of compound or medicinal salt or composition thereof | 深圳铂立健医药有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-113382997-A | Monohydrate of hydrochloric acid Rogatinib and solid state thereof | 拜耳股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020253458-A1 | CDK KINASE INHIBITOR | 北京睿熙生物科技有限公司 | 2020-12-24 | — | — | WO | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | CTSS 3871/4885CTSK 3925/4885CTSL 3723/4885 |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | CTSS 2413/4885CTSK 2096/4885CTSL 1875/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | CTSS 2356/4885CTSK 2054/4885CTSL 1875/4885 |
| US-20220098201-A1 | THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF | JAK2, JAK3, JAK1 | CTSS 4762/4885CTSK 3398/4885CTSL 4244/4885 |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | CDK4, FLT4, CDKL4 | CTSS 2367/4885CTSK 2113/4885CTSL 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.